Hepatocellular carcinoma (HCC) has a high rate of recurrence even after the curative treatment. Recently, it is suggested COX-2 inhibitor may offer a chemoprepentive approach for HCC. We have treated 236 patients with meloxicam for recurrent HCC after curative treatment. We evaluated the effects of meloxicam according to mRECIST six months after taking meloxicam of 114 cases received their curative surgery for HCC in our institute since January 2004. Of these 114 cases, tumor control rate was 40.4%, and overall survival rates at 3-, and 5-years were 88.7% and 63.3% in the PD group, whereas 95.4% and 86.8% respectively, in the CR/PR/SD groups (P=0.0603). Taking COX-2 inhibitor for recurrent HCC may prolong the time to progression and give the better prognosis.